The company manufactures and trades brass products like rods, billets, and precision components for the plumbing, electrical, and automotive sectors from its hub in Jamnagar.
The company lacks a durable moat, as evidenced by a sharp decline in net margins from 5.77% to 3.7% and an inability to pass on volatile copper and zinc costs. While it benefits from a manufacturing cluster in Jamnagar, the business remains a price-taking commodity processor with low barriers to entry.
Management utilized IPO proceeds primarily for debt repayment and working capital, which significantly deleveraged the balance sheet but resulted in a massive dilution of returns, with ROE falling from 49% to under 7%.
The investment collapsed as the company remained a price-taking commodity processor trapped in a brutal cycle of rising raw material costs and shrinking margins. Despite growing revenue, the business proved unable to pass on copper and zinc volatility to customers, leading to a total erosion of profitability. The massive dilution from the IPO, combined with a negative cash conversion cycle, forced the company to take on expensive debt to fund inventory, eventually destroying shareholder value as earnings per share continued their downward trajectory while promoters remained insulated through external remuneration structures.
RichFakir rates Narmadesh Brass Industries Ltd's business quality as poor — 37/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Narmadesh Brass Industries Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Narmadesh Brass Industries Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Narmadesh Brass Industries Ltd's fair value is about ₹90 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →